Zevra Therapeutics (ZVRA) Other Non Operating Income (2014 - 2026)

Zevra Therapeutics has reported Other Non Operating Income for 6 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income changed N/A year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$144.3 million (down 5690.09% YoY), and the FY2025 full-year result was -$133.7 million, down 2254.24% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$7.2 million, up from -$265.9 million in the prior quarter.
• The five-year high for Other Non Operating Income was $135.4 million in Q2 2025, with the low at -$265.9 million in Q4 2025.
• Historically, Other Non Operating Income has averaged -$18.2 million across 3 years, with a median of -$5.1 million in 2024.
• The largest YoY upside for Other Non Operating Income was 7470.08% in 2025 against a maximum downside of 3630.87% in 2025.
• Zevra Therapeutics' Other Non Operating Income stood at $7.5 million in 2024, then sank by 3630.87% to -$265.9 million in 2025, then soared by 97.29% to -$7.2 million in 2026.
• The last three Other Non Operating Income figures came in at -$7.2 million (Q1 2026), -$265.9 million (Q4 2025), and -$6.6 million (Q3 2025), per Business Quant data.